DOSEGUY

Nooglutyl

guinea pig

Also seen as: N-(5-hydroxynicotinoyl)-L-glutamic acid, N-5-hydroxynicotinoyl-L-glutamic acid

The Dose Guy’s verdict
Sep 1, 2026
2 sources

Nooglutyl is a glutamic acid derivative studied entirely in Russian rodent models from the 1990s and 2000s. No human study exists. No clinical trial. No safety data in any species above rats. The animal work covers aging, ischemic stroke, brain trauma, and prenatal damage, and the results were positive across models, but none of it moved toward people. This is a research line that stopped publishing. I’d skip it. If you want an AMPA-modulating nootropic, aniracetam has decades of community use behind it.

Would I take it?Not this one. Old Russian rat data and nothing since.

What it is

Nooglutyl is a synthetic derivative of L-glutamic acid and oxynicotinic acid, described as a positive modulator of AMPA-type glutamate receptors. The theory is that boosting AMPA signaling strengthens synaptic transmission and memory encoding, the same receptor family that compounds like sunifiram and the ampakines target. The entire evidence base sits in a handful of Russian-era pharmacology journals, testing it in mouse and rat models of brain damage.

The compound sits at the far end of the cognition shelf as a research chemical with no community behind it. Among the nootropics I cover, this one has almost no real-world footprint.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Everything here is rats and mice from Russian pharmacology journals. The body of work is narrow but internally consistent:

In accelerated-aging mice, nooglutyl at 20 mg/kg improved passive avoidance memory retrieval and normalized locomotor and anxiety behavior.Exp Clin Pharmacol 2007 · SAMP10 mice
After middle cerebral artery occlusion, nooglutyl at 10 mg/kg reduced the affected brain zone from 22.51% to 7.6% of hemisphere volume and restored a previously learned avoidance reflex.Exp Clin Pharmacol 2004 · ischemic rats
No human clinical study of nooglutyl exists, and no randomized human efficacy or safety trial has been registered.as of Aug 2026

Realistic protocols

I’m not building a protocol from rat doses in journal abstracts from Soviet-era labs. The animal studies used 10 to 25 mg/kg, which scales to hundreds of milligrams in a person, but that scaling is a guess nobody has validated. The community experience is nearly nonexistent, so there is no real-world dosing consensus to report. If you somehow source it and decide to run it, the only honest advice is: low dose, short duration, and do not pretend that positive results in rat models mean you know what this compound does in your body.

Side effects

No safety data exists in any species at human-relevant doses:

unknownZero human safety data. Zero published adverse-event reporting. The compound has been used almost exclusively in controlled rat experiments where side effects were not the focus.
unknownNo metabolism, drug-interaction, or reproductive-toxicity data in any species studied.
anecdotalCommunity reports are too sparse to characterize a profile. Most nooglutyl discussion is theoretical rather than experiential.

Where to buy

No live listings from tracked vendors right now.